Tempus ECG-AF vs AVIEW
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation within the next 12 months, leveraging existing 12-lead ECG data. This tool is ideal for integrating into routine cardiology or geriatric screenings to facilitate earlier detection and subsequent clinical management of AF risk.
View Tempus ECG-AF →Choose AVIEW if…
Choose AVIEW if your clinical setting requires a comprehensive AI platform for the multi-faceted analysis of CT scans, specifically for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification. This solution is best suited for radiology departments seeking to enhance diagnostic precision, automate quantitative assessments, and streamline workflows across multiple thoracic imaging indications.
View AVIEW →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | AVIEW |
|---|---|---|
| Pricing | Contact vendor | Subscription; one-off payment |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEWAVIEW explicitly focuses on an optimized user interface and user experience, along with 3D visualizations and comprehensive reports, suggesting a more interactive and user-friendly front-end application. Tempus ECG-AF, by contrast, is described as not having a dedicated user interface and integrates via standard communication protocols (e.g., API, file exchange) with other medical systems, making it more of a backend processing tool.
Clinical Value
AVIEWAVIEW provides broader and more comprehensive clinical value by analyzing multiple critical conditions (lung cancer, COPD, CAD) from a single CT scan, with extensive quantification and reporting features. Its widespread adoption in national lung cancer screening programs across Europe further underscores its proven clinical impact. Tempus ECG-AF offers significant value in predicting AF risk from ECGs with a high negative predictive value, but its scope is more specialized.
Pricing & Value
Tempus ECG-AFTempus ECG-AF has a clearly defined and established CMS reimbursement pathway with a specific Medicare rate of $128.90, effective January 1, 2025, providing a transparent and predictable financial value for providers. While AVIEW has recently gained a new HCPCS code for CAC/AVC analysis, the specific reimbursement amount is not yet detailed, making Tempus's value proposition more concrete at this time.
Enterprise Readiness
AVIEWAVIEW offers superior enterprise readiness due to its highly flexible deployment options (cloud, hybrid, on-premise, virtualized) and explicit, robust integration capabilities with PACS/RIS/CIS, which are critical for large-scale radiology workflows. Both are HIPAA compliant and FDA cleared, but AVIEW's broader deployment and integration strategy, including upgrades in integration and security, makes it more adaptable for diverse enterprise environments.
Innovation
AVIEWAVIEW demonstrates a broader and more integrated approach to innovation by combining multiple AI-powered analyses for lung cancer, COPD, and CAD from a single CT scan, evolving into an 'integrated diagnostic ecosystem.' While Tempus ECG-AF is innovative for its predictive AF risk from ECGs and its 'first-in-category' FDA clearance, AVIEW's multi-disease, multi-feature platform shows a wider scope of AI application and workflow transformation.
Support & Docs
TieBoth Tempus ECG-AF and AVIEW provide contact information for support, with Tempus listing a phone number and email for its Cardiology Support team, and Coreline Soft providing a customer service email. Both also mention the availability of documentation, such as a 'Document Library' for Tempus and 'PDF Catalogs | Technical Documentation' for AVIEW. Given the similar level of detail provided, it is not possible to definitively pick a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | AVIEW |
|---|---|---|
| Name | Tempus ECG-AF | AVIEW |
| Primary AI Focus | Cardiology AI | Cardiology AI, Oncology AI, Radiology & Imaging AI |
| Target Specialties | Cardiology, Geriatrics, Internal Medicine | Cardiology, Pulmonology, Radiology |
| Input Data Type | 12-lead ECG recordings | CT scans |
| Specific Clinical Use Case | Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months | Early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification |
| Target Patient Population | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery | Not specified |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and AVIEW.